Shares of Merck vaulted 10% to $148.64 Wednesday morning after the pharma giant and partner Moderna reported that their personalized mRNA cancer vaccine hit both key goals in a large, late-stage trial — results that could herald a new, powerful approach in oncology. For a company staring down the looming expiration of patent protection on its crown-jewel drug Keytruda, the timing could not be more consequential.

  • A First-of-Its-Kind Win Validates a Whole New Category of Cancer Treatment. This is the first randomized Phase 3 clinical trial aimed at definitively proving the benefit of so-called "neoantigen" vaccines — treatments custom-built from the unique mutations in each patient's tumor. The trial enrolled 1,137 patients with completely resected stage IIB–IV melanoma.

The combination produced statistically significant improvements in recurrence-free survival and distant metastasis-free survival.

The companies observed no new safety signals. This is the clinical proof-of-concept investors had been waiting on for years — and the data arrived earlier than analysts expected: RBC Capital Markets called it "a surprisingly positive development as we were expecting a year-end readout."

  • The Revenue Question: Billions in Potential, but the Split Is 50/50. Financial analysts estimate that an approved product could generate more than $6 billion in annual sales in melanoma alone, and much more should the same approach work in lung, kidney, and bladder cancer.

Merck and Moderna will share costs and any profits equally, meaning Merck's net take is roughly half. Barclays analysts last month estimated $3 billion in melanoma revenue by 2035. Meaningful, but modest against Keytruda's scale.

  • The Patent Cliff Still Looms Over Everything. Keytruda, currently the pharmaceutical industry's highest-grossing medication, generated $32 billion in revenue last year and faces biosimilar competition in coming years. Merck expects Keytruda to hit peak sales of $35 billion by 2028, after which the decline begins. Analysts have tipped the personalized vaccine to generate "multi-billion dollar peak sales," but even bullish scenarios replace only a fraction of the Keytruda revenue at risk.

  • Expansion Into Other Cancers Will Determine Whether This Is a Niche Win or a Franchise. Merck and Moderna are running nine Phase 2 and Phase 3 trials across melanoma, non-small cell lung cancer, bladder cancer, and kidney cancer, plus Phase 1 trials in pancreatic, gastric, and lung cancers.

The "big question" is whether the vaccine works in cancers where immunotherapies alone have failed. That answer, still years away, will ultimately decide whether today's 10% pop marks the start of a sustained climb — or just a very good day.